Existing drug could reduce breast cancer risk in pre-menopausal womenExisting drug could reduce breast cancer risk in pre-menopausal women
A University of Manchester study reveals a drug approved for use in other conditions could be repurposed as a preventive breast cancer treatment in women before menopause.
Macrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancerMacrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancer
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.
GLP-1 Agonists Tied to Lower Risk of Death in Dialysis PatientsGLP-1 Agonists Tied to Lower Risk of Death in Dialysis Patients
(MedPage Today) — Use of GLP-1 receptor agonists was associated with a lower risk of mortality for dialysis patients with type 2 diabetes, according to a retrospective cohort study of Medicare enrollees. Among over 151,000 patients, use of GLP… (MedPage Today) — Use of GLP-1 receptor agonists was associated with a lower risk of Read More
Mandatory nutrient warning labels could prevent 100,000+ obesity-related deathsMandatory nutrient warning labels could prevent 100,000+ obesity-related deaths
Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.
Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?
(MedPage Today) — Note that some links may require registration or subscription. A Finnish study found that voters had a lower risk for all-cause death over 21 years of follow-up compared with non-voters. (Journal of Epidemiology & Community… (MedPage Today) — Note that some links may require registration or subscription. A Finnish study found Read More
White House nears deal to lower prices for weight loss drugs Wegovy and ZepboundWhite House nears deal to lower prices for weight loss drugs Wegovy and Zepbound
The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said. The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of Read More
World’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDAWorld’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDA
(MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. (STAT) An Institute for Clinical and Economic Review report concluded… (MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. Read More
Adjuvant T-DXd Cuts Recurrence Risk in Early Breast CancerAdjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer
(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…
STAT+: News you need to know about AI medical coding and GLP-1 microdosingSTAT+: News you need to know about AI medical coding and GLP-1 microdosing
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Telehealth companies Noom, Found, and Hims & Hers have all recently launched programs to prescribe “microdosed” GLP-1s. The companies say that in small doses Read More
New model forecasts 10-year heart risk after breast cancer treatmentNew model forecasts 10-year heart risk after breast cancer treatment
A multi-institution research team led by Georgetown University Medical Center has developed and validated a model estimating the 10-year risk of heart failure or cardiomyopathy after early-stage breast cancer treatment. Separating women into low, moderate, and high risk ranged from 1.7% in the lowest to 19.4% in the highest group.